Second, at least in diabetic patients with CKD, SGLT2 inhibitors with partial SGLT1 inhibition, e.g., sotagliflozin and canagliflozin, may reduce the risk of total stroke, particularly in those with eGFR < 45 mL/min/1.73 m2 [39,40]. This evidence concerns the gene SLC5A2 and chronic kidney disease.